Here are the DEF 14A proxy statements from MacroGenics, Inc. (MGNX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGNX filings page.
MacroGenics will hold a virtual annual stockholder meeting on May 19, 2026. Investors are asked to elect three Class I directors, ratify Ernst & Young as auditor for 2026, approve 2025 executive pay on an advisory basis, and approve an amendment to the 2023 Equity Incentive Plan adding 1,250,000 shares for future equity awards. The company has 63,560,068 common shares outstanding as of March 27, 2026. Management highlights equity compensation as a key tool to attract and retain talent in a competitive biotech market and notes safeguards such as no option repricing without stockholder approval and a clawback policy for incentive pay.